Compounded glp-1s Trends & Statistics
Sales of Mounjaro and Zepbound missed estimates in Q3
Eli Lilly’s blockbuster GLP-1 sales fell short of expectations in Q3: The pharma giant blames wholesalers for not buying more drugs. We think the rise of compounded GLP-1s is also a factor.
Drugmaker asks FDA to ban compounding pharmacies from making Ozempic’s key ingredient
Novo asks FDA to ban compounders from making GLP-1 copies: The drugmaker argues Ozempic’s key ingredient is too complex to make safely, even during shortages. With patient access to affordable GLP-1s on the line, the FDA has a difficult decision to make.
WeightWatchers will start offering compounded GLP-1 weight-loss drugs
WeightWatchers is the latest company to offer compounded GLP-1s: Consumer demand for cheaper versions of GLP-1s is forcing even weight-loss industry legacy players to sell the meds.
Noom’s new GLP-1 offering comes with a ‘taper-off guarantee’ for patients
Noom gets into compounded GLP-1s with a taper-off guarantee: It’s building a weight loss program around the idea that patients will eventually want to stop taking the medications. We explore the pros and cons.
Powerful data and analysis on nearly every digital topic.
Become a ClientWant more marketing insights?
Sign up for EMARKETER Daily, our free newsletter.
Thanks for signing up for our newsletter!
You can read recent articles from EMARKETER here.- Learn about what technologies are transforming your industry
- Gain exclusive perspectives from top industry leaders
- Access thousands of data sets and forecasts via our iconic charts